^
    Back
    Association details:
    Biomarker:KRAS G12V
    Cancer:Colorectal Cancer
    Drug:Vectibix (panitumumab) (EGFR inhibitor) +
    avutometinib (VS-6766) (BRAF inhibitor, MEK inhibitor, cRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR 2023
    Title:

    530 / 30 - Preclinical evaluation of avutometinib (VS-6766; RAF/MEK clamp) in combination with EGFR inhibition in colorectal cancer patient-derived xenograft (PDX) models harboring KRAS mutations

    Published date:
    03/15/2023
    Excerpt:
    The combination of avuto and panitumumab showed significant anti-tumor activity in a CRC PDX model harboring KRAS G12V…